

HUNTINGTON'S DISEASE

PATHOGENIC MECHANISMS AND IMPLICATIONS FOR THERAPEUTICS

Edited by

X. WILLIAM YANG

*Center for Neurobehavioral Genetics, Jane and Terry Semel Institute for Neuroscience and Human Behavior,
University of California, Los Angeles, Los Angeles, CA, United States; Department of Psychiatry and Biobehavioral Sciences,
David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States*

LESLIE M. THOMPSON

*Department of Psychiatry and Human Behavior, University of California, Irvine, CA, United States;
Department of Neurobiology and Behavior, University of California, Irvine, CA, United States;
Department of Biological Chemistry University of California, Irvine, CA, United States*

MYRIAM HEIMAN

*The Picower Institute for Learning and Memory, Cambridge, MA, United States;
Department of Brain and Cognitive Sciences, MIT, Cambridge, MA, United States*



ACADEMIC PRESS

An imprint of Elsevier

Contents

Contributors xiii

Preface xvii

1. Huntington's disease: Clinical features, genetic diagnosis, and brain imaging

CARLOS ESTEVEZ-FRAGA, MITSUKO NAKAJIMA AND SARAH J. TABRIZI

Introduction 1
Clinical course 6
Juvenile Huntington's disease 12
Genetic diagnosis and genetic counseling 14
Imaging 16
Conclusion: Clinical aspects relevant for the development of disease-modifying therapies in Huntington's disease 25
List of abbreviations 27
Acknowledgments 27
References 27

2. Revolutionizing clinical research and communication in Huntington's disease: The Huntington's disease integrated staging system (HD-ISS)

CRISTINA SAMPAIO, JEFFREY D. LONG, ALEXANDRA MANSBACH, SARAH J. TABRIZI AND EMILY C. GANTMAN

Introduction 41
Disease classification, measurement, and staging 42
The development of the HD-ISS 44
Applying the HD-ISS in research: New possibilities 49
Applying the HD-ISS in research: Practical questions 50
Applying the HD-ISS in research: Implications for people with Huntington's disease 53
Conclusion 53
References 54

3. Huntington's disease genetics: Implications for pathogenesis

MARCY E. MACDONALD, JONG-MIN LEE AND JAMES F. GUSELLA

Description of inheritance 57
Chromosomal mapping of the HD genetic defect and its consequences 58
The HD genetic defect 60
The expanded *HTT* CAG repeat confers a gain of function 63
HD genotype—phenotype correlation 64
Modifiers of HD onset from human genetics 66
A model for HD pathogenesis from human genetics 68
Underpinnings of the modifier effects 69
Modifiers of other disease landmarks 72
HD diagnostics 74
What is the ultimate cause of neuronal loss? 74
Potential for developing an HD treatment from genetic knowledge 76
Conclusion 77
Disclosure 77
References 78

4. The instability of the Huntington's disease CAG repeat mutation

VANESSA C. WHEELER, JOSEPH C. STONE, THOMAS H. MASSEY AND RICARDO MOURO PINTO

Introduction: The critical role of CAG repeat length 85
Intergenerational repeat instability 86
Somatic repeat instability 91
Insights into CAG repeat instability from mouse models 93
Insights from human genetics 98
Conclusions and perspective 101
Dedication 104
References 104

5. Mechanisms of somatic CAG-repeat expansions in Huntington's disease

AMIT L. DESHMUKH, TERENCE GALL-DUNCAN AND CHRISTOPHER E. PEARSON

- Introduction 117
- Current understanding of somatic repeat instability 121
- Slip-out formation 122
- Requirement of transcription and transcription-coupled repair for somatic repeat instability 123
- Melting unusual structures at the repeat and modulating torsional tension 124
- Many nucleases can act on slipped-DNA structures which may impact repeat instability 125
- Gap-filling and ligation of the DNA backbone 127
- What is still unclear? 127
- Conclusion 128
- References 128

6. RNA-mediated pathogenic mechanisms in Huntington's disease

GILLIAN P. BATES, SANDRA FIENKO, CHRISTIAN LANDLEES AND AIKATERINI-SMARAGDI PAPADOPOULOU

- Expression of the huntingtin gene 135
- Regulation of huntingtin transcription 136
- Alternative processing of huntingtin pre-mRNA 137
- Nuclear RNA "clusters" and RNA "foci" in HD mouse models and HD patient samples 143
- Global aberrant RNA processing in HD 145
- RNA-based mechanism of pathogenesis 147
- Implications for therapy 151
- References 152

7. Huntingtin protein—protein interactions: From biology to therapeutic targets

EDUARDO SILVA RAMOS, TODD M. GRECO, ILEANA M. CRISTEA AND ERICH E. WANKER

- Introduction 159
- Two-hybrid HTT protein interaction mapping efforts 160
- Cataloging of HTT interacting partners using (immuno) affinity-based purification approaches 165
- Compilation and computational analysis of HTT PPIs from large- and small-scale PPI mapping studies 169
- Outlook 174
- Acknowledgments 176
- References 176

8. Repeat-associated non-AUG (RAN) translation and Huntington's disease: Pathology, mechanistic and therapeutic perspectives

MONICA BAÑEZ-CORONEL, JOHN DOUGLAS CLEARY AND LAURA P.W. RANUM

- Introduction to RAN translation 187
- RAN proteins in Huntington's disease 188
- RAN and polyGln proteins accumulate in distinct and vulnerable brain regions 188
- Animal models of HD and RAN translation 192
- RAN protein toxicity 194
- Mechanistic focused therapeutics 196
- Conclusions 197
- References 198
- Further reading 203

9. Proteostasis function and dysfunction in Huntington's disease

JULIANA ABRAMOVICH, KORBIN KLECZKO, VINCENT MASTO AND JUDITH FRYDMAN

- Introduction 205
- Impact of mHTT protein on HD pathology and protein aggregation propensity 209
- mHTT interactions with the translation machinery 210
- mHTT interactions with molecular chaperones 212
- Pathways implicated in mHTT clearance 215
- mHTT sequestration—beneficial or deleterious? 217
- A vicious cycle links proteostasis dysfunction and HD pathology 218
- Perspectives 220
- References 220

10. Autophagy and Huntington's disease

KATHERINE R. CROCE, HILARY GROSSO JASUTKAR AND AI YAMAMOTO

- Introduction 229
- Autophagy, three pathways trafficking cytosolic cargo to the lysosome 231
- Autophagy: A therapeutic avenue for HD? 234
- Selective autophagy: No longer simply "bulk degradation" 241
- Dysfunctional autophagy in Huntington's disease 247
- Conclusion 248
- References 248

11. SUMO modification in Huntington's disease: Unraveling complex mechanisms for therapeutic insights

CHARLENE SMITH, JOAN S. STEFFAN AND
LESLIE M. THOMPSON

- Introduction 259
- Unveiling the intricate machinery behind SUMOylation 260
- SUMO's journey in HD: Tracing SUMO's path in Huntington's disease research 263
- Guiding the way: E3 SUMO ligases and their role in regulating HTT protein dynamics 266
- Balancing act: How SUMO tips the scale of protein homeostasis 267
- SUMO at the crossroads of cellular stress: Navigating the relationship with stress granules 269
- Disruption of the nuclear pore and altered nucleocytoplasmic transport in HD: A role for SUMO? 270
- Synaptic SUMO: Bridging the gap between molecular modification and neuronal communication 271
- Small modifier, big role: How SUMO orchestrates DNA damage repair 272
- Summary and future directions: Implications for therapy 272
- References 273

12. Selective vulnerability in Huntington's disease: From excitotoxicity, mitochondrial dysfunction, and transcription dysregulation to therapeutic opportunity

JACOB S. DEYELL, RAVINDER GULIA AND
ALBERT R. LA SPADA

- Selective vulnerability in Huntington's disease 286
- Possible mechanisms underlying corticostriatal degeneration in HD 286
- Discovery of mitochondrial dysfunction in HD 291
- PGC-1 α 294
- p53 and mitochondrial dysfunction in HD 296
- Heat Shock Transcription Factor 1 297
- Peroxisome proliferator-activated receptors 300
- Therapeutic opportunities 302
- Conclusion and future directions 304
- Acknowledgments 305
- References 305

13. Pathophysiology of synapses and circuits in Huntington disease

MARJA D. SEPERS, JAMES MACKAY AND LYNN A. RAYMOND

- Clinical and genetic features of HD 311
- Cortical-basal ganglia-thalamic-cortical loops regulate movement and are modulated by dopamine 311
- Neuropathology 312
- Measurable subclinical changes precede definitive motor diagnosis 314
- Animal models of HD facilitate investigating brain changes before overt clinical diagnosis 314
- Striatal microcircuit synapses 315
- Synaptic alterations in basal ganglia nuclei downstream of striatal SPN 318
- Neuronal excitability 320
- Input-specific plasticity: Long-term potentiation and depression 323
- Homeostatic plasticity 324
- Altered corticostriatal and thalamostriatal connectivity in HD 325
- Cortex motor and sensory function 326
- Cortex reward pathways 327
- Targeting synaptic and circuit changes to advance therapeutics in Huntington disease 328
- References 329

14. The role of glial pathology in Huntington's disease

STEVEN A. GOLDMAN

- The role of glial progenitor cells in HD pathogenesis 338
- Astrocytic dysfunction in HD 338
- The effects of HD pathology on oligodendrocytes and myelin 345
- Synopsis 346
- References 349

15. Systems biology study of Huntington's disease

LEONARDO E. DIONISIO, PETER LANGFELDER,
JEFFREY S. AARONSON, JIM ROSINSKI AND
X. WILLIAM YANG

- Introduction 353
- Transcriptomic profiling of HD mice 355

Insights from transcriptomic studies of HD mouse models 359
 Mechanisms implicated in striatal transcriptinopathy in HD 368
 Epigenomic dysregulation in HD mice 373
 Application of systems biology to study HD perturbations 376
 Database of HD experimental data 380
 Conclusions and perspectives 384
 References 386

16. Unbiased genome-wide approaches to identify vulnerability factors in Huntington's disease

SUPHINYA SATHITLOETSAKUN AND MYRIAM HEIMAN

Yeast model screening studies 397
 Invertebrate model screening studies 399
 Mammalian cell screening studies 402
 Mammalian in vivo screening 404
 Future directions 405
 References 407

17. Striatal neuronal models of Huntington's disease via direct conversion: Modeling age-dependent disease phenotypes

YOUNG MI OH, SEONG WON LEE AND ANDREW S. YOO

MicroRNA-mediated conversion of human fibroblasts to neurons 411
 Age maintenance in directly reprogrammed neurons 413
 Recapitulation of adult-onset neuropathology of Huntington's disease using miRNAs-mediated reprogrammed neurons 414
 Modeling disease-stage progression of Huntington's disease 416
 Conclusion 420
 Acknowledgments 420
 References 420

18. Genetic mouse models to explore Huntington's disease mechanisms and therapeutic strategies

MICHELLE GRAY, SCOTT O. ZEITLIN, AIDA MORAN-REYNA AND JEH-PING LIU

Transgenic mHTT N-terminal fragment mouse models of HD 427
 Full-length mHTT knock-in mouse models 430

Full-length human *HTT* transgenic models 434
 Conclusions and perspectives 445
 References 446

19. Huntington's disease: From large animal models to HD gene therapy

SEN YAN, XIAO-JIANG LI AND SHIHUA LI

Introduction to Huntington's disease neuropathology 455
 Treatment of large animal models of HD 462
 Conclusions 464
 Acknowledgments 466
 References 466
 Further reading 471

20. Deep learning and deep phenotyping of HD iPSCs: Applications to study biology and test therapeutics

STEVEN FINKBEINER

Background: Complexity in biology 473
 A brief introduction to AI 475
 Applications of DL to biology 482
 Impact 496
 References 497

21. The promise of an underappreciated therapeutic target: Sleep and circadian rhythm dysfunction in Huntington's disease

CHRISTOPHER S. COLWELL, WEIYI TAN AND A. JENNIFER MORTON

Sleep disturbance in Huntington's disease: The evidence 500
 Sleep disturbance in Huntington's disease: Preclinical models 501
 Which comes first, HD or sleep dysfunction, and does it matter? 504
 Circadian-based interventions in preclinical models 504
 Pharmacological interventions 508
 Conclusions 513
 References 513
 Further reading 521

22. Huntingtin lowering therapeutics

NEIL ARONIN, MIGUEL SENA-ESTEVEZ, ANASTASIA KHVOROVA, MARIAN DIFIGLIA AND MICHAEL BRODSKY

DNA oligonucleotides 524

- Oligonucleotides that use RNA interference 524
- siRNA oligonucleotides as therapeutic agents in HD 525
- Gene editing to lower or correct mutant huntingtin mRNA or protein 527
- AAV gene delivery for Huntington's disease:
Background 531
- Micro-RNA: Its utility for viral-based delivery to brain in HD 531
- Challenges for AAV gene therapy in HD 534
- Stabilization of pseudo-exons in the human huntingtin gene, leading to nonsense-mediated decay of huntingtin mRNA 539
- CAG expansion as a target for therapy: Zinc-finger proteins 539
- Small molecule interaction with the CAG repeat:
Naphthyridine-Azaquinolone 540
- Preventing somatic lengthening of CAG repeat length, a tractable therapeutic strategy 540
- Recent clinical trials testing lowering of mutant *HTT* 541
- Commentary and outlook 541
- Acknowledgments 542
- References 542
- Further reading 549
- 23. Gene editing for HD: Therapeutic prospects**
RICHARD Z. CHEN AND THOMAS F. VOGT
- Introduction 551
- Overview of *mHTT*-selective gene editing strategies 553
- SNP-based strategies 554
- (CAG)*n*-based strategies 558
- HTT* mutation correction strategies 559
- Targeting HD modifier genes 561
- Perspective 561
- Acknowledgments 563
- References 563
- 24. Current clinical trials of new therapeutic agents for Huntington's disease**
BLAIR R. LEAVITT
- Introduction 571
- Phase I clinical trials 571
- Phase II clinical trials 572
- Phase III clinical trials 572
- Regulatory approval of clinical trials 572
- Conclusions and future studies 584
- Potential novel therapeutic approaches for HD 584
- Challenges and opportunities in clinical trial design and conduct in HD 585
- References 587
- Index 591**